Method to determine treatment of acute heart failure
A method is described for treating a subject having acute heart failure (AHF) by measuring PERLECAN levels in the subject. The PERLECAN level in the subject is used to determine risk of mortality within one year for the subject. Treatment is selected on the basis of the outcome of the assay.
1. A method for decreasing risk of mortality at one year in a subject treated for having acute heart failure (AHF) comprising:
(i) obtaining a blood sample from the subject after the subject is treated with an anti-acute heart failure therapy;
(ii) having an assay conducted to measure the quantity of PERLECAN in the blood sample from said subject by contacting antibody or an aptamer capable of specifically detecting the endorepellin or LG3 domain of PERLECAN with the blood sample from the subject and measuring the quantity of the endorepellin or LG3 domain of PERLECAN in the blood sample by determining the binding of the antibody or aptamer to the endorepellin or LG3 domain of PERLECAN;
(iii) comparing the quantity of the endorepellin or LG3 domain of PERLECAN measured in (ii) with a reference value of the quantity of the endorepellin or LG3 domain of PERLECAN, said reference value from a patient who is known to die from acute heart failure within a year;
(iv) finding an elevation of the quantity of PERLECAN measured in (ii) from the reference value;
(v) attributing said elevation to a to a risk of mortality from acute heart failure within a year; and
(vi) modifying the anti-acute heart failure treatment of the subject based upon the PERLECAN level and administering said modified anti-acute heart failure treatment, thereby decreasing risk of mortality at one year.